Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: Regulation and phenotypic effects of Hypoxia-Inducible Factor

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Knowles, Helen J ^a   Schaefer, Karl Ludwig ^b   Dirksen, Uta ^c   Athanasou, Nicholas A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LUCIFERASE; SMALL INTERFERING RNA; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; MESSENGER RNA;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; EWING SARCOMA; HYPOGLYCEMIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PATHOGENESIS; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TRANSCRIPTION INITIATION; WESTERN BLOTTING; ANOXIA; BONE TUMOR; CELL ADHESION; CELL MOTION; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANOXIA; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; OSTEOSARCOMA; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SARCOMA, EWING'S;

EID: 77954560445     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-372     Document Type: Article

References (54)

1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225-239. 10.1007/s10555-007-9055-1, 17440684.
2. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54. 10.1016/S0092-8674(01)00507-4, 11595184.
3. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340. 10.1126/science.1066373, 11598268.
4. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47. 10.1038/nrc704, 11902584.
5. Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007, 64:2170-2180. 10.1007/s00018-007-7082-2, 17514355.
6. Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J. Overexpression of Hypoxia-Inducible Factor-1{alpha} in Human Osteosarcoma: Correlation with Clinicopathological Parameters and Survival Outcome. Jap J Clin Oncol 2007, 37:127-134.
7. Mizobuchi H, Garcia-Castellano JM, Philip S, Healey JH, Gorlick R. Hypoxia markers in human osteosarcoma: An exploratory study. Clin Orthopaed Rel Res 2008, 466:2052-2059.
8. Chen WL, Feng HJ, Li HG. Expression and significance of hypoxemia-inducible factor-1 alpha in osteosarcoma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2008, 106:254-257.
9. van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, Griffioen AW. Tumor cell plasticity in Ewing sarcoma an alternative circulatory system stimulated by hypoxia. Cancer Res 2005, 65:11520-11528. 10.1158/0008-5472.CAN-05-2468, 16357161.
10. Kubo T, Sugita T, Shimose S, Matsuo T, Arihiro K, Ochi M. Expression of hypoxia-inducible factor-1 alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J Bone Joint Surg-Br Vol 2008, 90B:364-370.
11. Knowles HJ, Athanasou NA. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol 2008, 215:56-66. 10.1002/path.2319, 18283716.
12. Holzer G, Obermair A, Koschat M, Preyer O, Kotz R, Trieb K. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediat Oncol 2001, 36:601-604.
13. Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C, Kessler T, Jurgens H, Berdel WE, Mesters RM. Clinical significance of vascular endothelial growth factor - a expression in Ewing's sarcoma. Eur J Cancer 2006, 42:1904-1911. 10.1016/j.ejca.2006.01.063, 16824746.
14. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000, 6:572-577.
15. Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y, Hiraga H, Isu K, Shindoh M, Higashino F, Okada F, Tada M, Yamawaki S, Ishii S. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Brit J Cancer 2002, 86:864-869. 10.1038/sj.bjc.6600201, 2364146, 11953816.
16. Dunst J, Ahrens S, Paulussen M, Burdach S, Jurgens H. Prognostic impact of tumor perfusion in MR-imaging studies in Ewing tumors. Strahlenther Onkol 2001, 177:153-159.
17. Jenkin RD, Al-Fawaz I, Al-Shabanah M, Allam A, Ayas M, Khafaga Y, Memon M, Rifai S, Schultz H, Younge D. Localised Ewing Sarcoma/PNET of bone - Prognostic factors and international data comparison. Med Pediat Oncol 2002, 39:586-593.
18. Kavalar R, Marinsek ZP, Jereb B, Cagran B, Golouh R. Prognostic value of CD99, CD117, p53 and bcl-2 in Ewing sarcoma family tumours. Eur J Oncol 2007, 12:243-253.
19. Mayes PA, Campbell L, Ricci MS, Plastaras JP, Dicker DT, El-Deiry WS. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol Ther 2005, 4:1068-1074. 10.4161/cbt.4.10.2255, 16294025.
20. Kim HH, Lee SE, Chung WJ, Choi Y, Kwack K, Kim SW, Kim MS, Park H, Lee ZH. Stabilization of hypoxia-inducible factor-1 alpha is involved in the hypoxic stimuli-induced expression of vascular endothelial growth factor in osteoblastic cells. Cytokine 2002, 17:14-27. 10.1006/cyto.2001.0985, 11886167.
21. Doege K, Heine S, Jensen I, Jelkmann W, Metzen E. Inhibition of mitochondrial respiration elevates oxygen concentration but leaves regulation of hypoxia-inducible factor (HIF) intact. Blood 2005, 106:2311-2317. 10.1182/blood-2005-03-1138, 15947089.
22. Akeno N, Czyzyk-Krzeska MF, Gross TS, Clemens TL. Hypoxia induces vascular endothelial growth factor gene transcription in human osteoblast-like cells through the hypoxia-inducible factor-2alpha. Endocrinol 2001, 142:959-962.
23. Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007, 26:2027-2038. 10.1038/sj.onc.1210008, 17043658.
24. Yeo EJ, Chun YS, Cho YS, Kim JH, Lee JC, Kim MS, Park JW. YGI: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003, 95:516-525. 10.1093/jnci/95.7.516, 12671019.
25. Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 2005, 11:2008-2017. 10.1158/1078-0432.CCR-04-0777, 15756027.
26. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49:40-51. 10.1002/gcc.20717, 19787792.
27. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003, 63:6130-6134.
28. Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005, 25:5675-5686. 10.1128/MCB.25.13.5675-5686.2005, 1157001, 15964822.
29. Covello KL, Simon MC, Keith B. Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 2005, 65:2277-2286. 10.1158/0008-5472.CAN-04-3246, 15781641.
30. Qing GL, Simon MC. Hypoxia inducible factor-2 alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 2009, 19:60-66. 10.1016/j.gde.2008.12.001, 19167211.
31. Warnecke C, Weidemann A, Volke M, Schietke R, Wu XQ, Knaup KX, Hackenbeck T, Bernhardt W, Willam C, Eckardt KU, Wiesener MS. The specific contribution of hypoxia-inducible factor-2 alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res 2008, 314:2016-2027. 10.1016/j.yexcr.2008.03.003, 18420194.
32. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU. Differentiating the functional role of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2 alpha target gene in Hep3B and Kelly cells. Faseb J 2004, 18:1462.
33. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ. Genome-wide Association of Hypoxia-inducible Factor (HIF)-1 alpha and HIF-2 alpha DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts. J Biol Chem 2009, 284:16767-16775. 10.1074/jbc.M901790200, 2719312, 19386601.
34. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003, 83:1477-1487. 10.1097/01.LAB.0000090156.94795.48, 14563949.
35. Nilsson H, Jogi A, Beckman S, Harris AL, Poellinger L, Pahlman S. HIF-2 alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation glucose deficiency and hypoxia. Exp Cell Res 2005, 303:447-456. 10.1016/j.yexcr.2004.10.003, 15652356.
36. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997, 386:403-407. 10.1038/386403a0, 9121557.
37. Natsuizaka M, Ozasa M, Darmanin S, Miyamoto M, Kondo S, Kamada S, Shindoh M, Higashino F, Suhara W, Koide H, Aita K, Nakagawa K, Kondo T, Asaka M, Okada F, Kobayashi M. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res 2007, 313:3337-3348. 10.1016/j.yexcr.2007.06.013, 17651733.
38. Vordermark D, Kraft P, Katzer A, Bolling T, Willner J, Flentje M. Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha). Cancer Lett 2005, 230:122-133. 10.1016/j.canlet.2004.12.040, 16253768.
39. Kwon SJ, Lee YJ. Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1 alpha in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells. Clin Cancer Res 2005, 11:4694-4700. 10.1158/1078-0432.CCR-04-2530, 16000563.
40. Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, Hiraoka M. The Akt/mTOR Pathway Assures the Synthesis of HIF-1 alpha Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors. J Biol Chem 2009, 284:5332-5342. 10.1074/jbc.M806653200, 19098000.
41. Kissane JM, Askin FB, Foulkes M, Stratton LB, Shirley SF. Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study. Hum Pathol 1983, 14:773-779. 10.1016/S0046-8177(83)80300-1, 6885037.
42. Araya R, Uehara T, Nomura Y. Hypoxia induces apoptosis in human neuroblastoma SK-N-MC cells by caspase activation accompanying cytochrome c release from mitochondria. FEBS letters 1998, 439:168-172. 10.1016/S0014-5793(98)01363-5, 9849900.
43. Brusselmans K, Bono F, Maxwell P, Dor Y, Dewerchin M, Collen D, Herbert JM, Carmeliet P. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J Biol Chem 2001, 276:39192-39196. 10.1074/jbc.C100428200, 11546756.
44. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E. Role of HIF-1 alpha or in hypoxia-mediated apoptosis cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490. 10.1038/28867, 9697772.
45. Halterman MW, Miller CC, Federoff HJ. Hypoxia-inducible factor-1 alpha mediates hypoxia-induced delayed neuronal death that involves p53. J Neurosci 1999, 19:6818-6824.
46. Papandreou I, Krishna C, Kaper F, Cai DL, Giaccia AJ, Denko NC. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res 2005, 65:3171-3178.
47. Brunelle JK, Shroff EH, Perlman H, Strasser A, Moraes CT, Flavell RA, Danial NN, Keith B, Thompson CB, Chandel NS. Loss of Mcl-1 protein and inhibition of electron transport chain together induce anoxic cell death. Mol Cell Biol 2007, 27:1222-1235. 10.1128/MCB.01535-06, 1800715, 17145774.
48. Kondo K, Kim WY, Lechpammer M, Kaelin WG. Inhibition of HIF2 alpha is sufficient to suppress pVHL-defective tumor growth. Plos Biol 2003, 1:439-444.
49. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007, 11:335-347. 10.1016/j.ccr.2007.02.006, 17418410.
50. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1 alpha induces cell cycle arrest by functionally counteracting Myc. Embo J 2004, 23:1949-1956. 10.1038/sj.emboj.7600196, 404317, 15071503.
51. Imamura T, Kikuchi H, Herraiz MT, Park DY, Mizukami Y, Mino-Kenduson M, Lynch MP, Rueda BR, Benita Y, Xavier RJ, Chung DC. HIF-1 alpha and HIF-2 alpha have divergent roles in colon cancer. Int J Cancer 2009, 124:763-771. 10.1002/ijc.24032, 2682346, 19030186.
52. Ben-Shoshan J, Schwartz S, Luboshits G, Maysel-Auslender S, Barzelay A, Polak-Charcon S, Tzahor E, Barshack I, Barak A, Levkovitch-Verbin H, Keren G, George J. Constitutive Expression of HIF-1 alpha and HIF-2 alpha in Bone Marrow Stromal Cells Differentially Promotes Their Proangiogenic Properties. Stem Cells 2008, 26:2634-2643. 10.1634/stemcells.2008-0369, 18687993.
53. Yin DZ, Jia TH, Gong WM, Yu HY, Wooley PH, Mott MP, Yang SY. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol 2008, 33:253-259.
54. Guan H, Zhou ZC, Wang H, Jia SF, Liu WB, Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005, 11:2662-2669. 10.1158/1078-0432.CCR-04-1206, 15814647.